Pharmacoeconomic review report : Sapropterin dihydrochloride (Kuvan)

Pharmacoeconomic review report Sapropterin dihydrochloride (Kuvan)

Sapropterin (SAP) (Kuvan) is indicated in conjunction with a phenylalanine (Phe)-restricted diet to reduce blood Phe levels in patients with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin (BH4)-responsive phenylketonuria (PKU). The initial dosage is 20 mg/kg/day administered orally for a per...

Descripción completa

Detalles Bibliográficos
Autor principal: Canadian Agency for Drugs and Technologies in Health (author)
Autor Corporativo: Canadian Agency for Drugs and Technologies in Health, author, issuing body (author)
Formato: Libro electrónico
Idioma:Inglés
Publicado: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health 2017.
Colección:Common drug review clinical review report.
Materias:
Oral medication.
Cost effectiveness.
Ver en Biblioteca Universitat Ramon Llull:https://discovery.url.edu/permalink/34CSUC_URL/1im36ta/alma991009820268106719
Tabla de Contenidos:
  • Abbreviations
  • Executive Summary
  • Information on the Pharmacoeconomic Submission
  • 1. Summary of the Manufacturer's Pharmacoeconomic Submission
  • 2. Manufacturer's Base Case
  • 3. Limitations of Manufacturer's Submission
  • 4. Conclusions
  • Appendix 1. Cost Comparison
  • Appendix 2. Summary of Key Outcomes
  • Appendix 3. Additional Information
  • Appendix 4. Reviewer Worksheets
  • Appendix 5. Summary of Other Cost-Effectiveness Analyses
  • Appendix 6. Summary of Long-Term Phenylketonuria Studies
  • Appendix 7. Coverage of Phenylketonuria Formulas and Medical Foods Across Canada
  • References.

Ejemplares similares